Luke Maese, DO, Rachel Rau, MD - Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy

Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric and AYA ALL therapy. Watch experts provide guidance on the modern use of asparaginase therapy and share tactics for addressing real-world barriers to effective care, including hypersensitivity, silent inactivation, and asparaginase discontinuation, and get their perspectives on optimized asparaginase dosing and toxicity mitigation approaches. Learn how you can utilize modern asparaginase strategies to improve outcomes in ALL by watching today! Upon completion of this activity, participants should be better able to: Discuss current efficacy evidence and unmet needs related to the optimized use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds; Devise strategies to address therapeutically relevant considerations related to asparaginase use for pediatric ALL such as appropriate dosing, pre-empting truncation/discontinuation, and drug-related toxicity; Identify the emergence of asparaginase hypersensitivity, silent inactivation, or toxicity through the use of evidence-based monitoring plans in pediatric ALL; and Select treatment strategies to avoid asparaginase discontinuation and ensure adequate exposure to therapy, including switching to Erwinia asparaginase options after confirming hypersensitivity.